Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04547140 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate the Safety and Efficacy of Liquid Alpha1-Proteinase Inhibitor (Human) in Hospitalized Participants With Coronavirus Disease (COVID-19)
A Phase 2 study, sponsored by Grifols Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 57
- Enrollment target
NCT04547140 is a Phase 2 study that was terminated before completion, run by Grifols Therapeutics. The registered enrollment target is 57 participants.
The verdict
NCT04547140, a Phase 2 study, was terminated before completion, sponsored by Grifols Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 57 participants
- Enrollment target
Study Summary
The purpose of the study is to determine if Liquid Alpha1-Proteinase Inhibitor (Human) (Liquid Alpha1-PI) plus SMT can reduce the proportion of participants dying or requiring intensive care unit (ICU) admission on or before Day 29 or who are dependent on high flow oxygen devices or invasive mechanical ventilation on Day 29 versus placebo plus SMT in hospitalized participants with COVID-19.
Interventions
- DRUG Placebo
- BIOLOGICAL Liquid Alpha1-Proteinase Inhibitor (Human)
- DRUG Standard Medical Treatment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2021-01-29 |
| Est. Completion | 2022-01-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04547140
The ClinicalTrials.gov registry entry for NCT04547140 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 57 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Grifols Therapeutics, which has 34 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT04547140 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04547140 about?
NCT04547140 is a clinical study titled "Study to Evaluate the Safety and Efficacy of Liquid Alpha1-Proteinase Inhibitor (Human) in Hospitalized Participants With Coronavirus Disease (COVID-19)". The purpose of the study is to determine if Liquid Alpha1-Proteinase Inhibitor (Human) (Liquid Alpha1-PI) plus SMT can reduce the proportion of participants dying or requiring intensive care unit (ICU) admission on or before Day 29 or who are dependent on high flow oxygen devices or invasive mechani...
What is the current status of trial NCT04547140?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 57 participants. The study started on 2021-01-29. Estimated completion is 2022-01-28.
What interventions are being tested in trial NCT04547140?
The interventions under investigation include: Placebo (DRUG), Liquid Alpha1-Proteinase Inhibitor (Human) (BIOLOGICAL), Standard Medical Treatment (DRUG).
Who is sponsoring clinical trial NCT04547140?
This trial is sponsored by Grifols Therapeutics, which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.